Nexvet Reports Financial Results for Third Quarter of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2015

DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET ) today announced its financial results for the three and nine month periods ended March 31, 2015.

Corporate Highlights

  • In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to the public of $10.00 per share. The underwriters partially exercised their over-allotment option and purchased an additional 0.2 million shares. Following the sales of these securities, we received aggregate gross proceeds of $41.8 million and net proceeds of $38.0 million.  
  • In March 2015, we received the results of a sample size reassessment for the ongoing     NV-01 pivotal safety and efficacy study, which indicated that in order to have a high probability of a statistically significant endpoint at the day 28 primary assessment, it would be necessary to substantially increase the current size of the study. In April 2015, we announced that we intend to continue the current study to completion without a change in study size, while also commencing a new placebo-controlled multi-site field safety and efficacy study to assess various doses and dosing regimens of NV‑01. This new study is expected to enroll approximately 150 dogs, cost approximately $1.0 million and be completed in the fourth calendar quarter of 2015.  
  • In March 2015, former Division Head of Novartis Animal Health Dr. George Gunn became non-executive chairman of the Nexvet Board of Directors. Former chairman Chris Brown remains on the Board as a non-executive director.

Third Quarter 2015 Financial Results

As of March 31, 2015, Nexvet had cash of $55.5 million.

For the three months ended March 31, 2015, Nexvet reported a net loss of $2.7 million, compared to $1.5 million for the three months ended March 31, 2014. Net loss per share attributable to ordinary shareholders (basic and diluted) for the three months ended March 31, 2015 was $0.36, compared to $1.47 for the three months ended March 31, 2014.

The net loss of $2.7 million for the three months ended March 31, 2015 included operating expenses of $5.1 million, reflecting $2.7 million in research and development expenses and $2.4 million in general and administrative expenses. Other income comprised $2.4 million, principally research and development incentive income of $1.0 million and an exchange gain of $1.3 million.

The net loss of $1.5 million for the three months ended March 31, 2014 included operating expenses of $2.7 million, reflecting $1.6 million in research and development expenses and $1.1 million in general and administrative expenses. Other income comprised $1.2 million, principally research and development incentive income of $0.6 million and government grant income of $0.6 million.

For the nine months ended March 31, 2015, Nexvet reported a net loss of $7.4 million, compared to $3.5 million for the nine months ended March 31, 2014. Net loss per share attributable to ordinary shareholders (basic and diluted) for the nine months ended March 31, 2015 was $2.30, compared to $3.48 for the nine months ended March 31, 2014.

The net loss of $7.4 million for the nine months ended March 31, 2015 included operating expenses of$15.1 million, reflecting $7.4 million in research and development expenses and $7.7 million in general and administrative expenses. Other income comprised $7.7 million, principally research and development incentive income of $2.7 million, an exchange gain of $4.6 million and government grant income of $0.4 million.

The net loss of $3.5 million for the nine months ended March 31, 2014 included operating expenses of $6.2 million, reflecting $3.6 million in research and development expenses and $2.6 million in general and administrative expenses. Other income comprised $2.7 million, principally research and development incentive income of $1.4 million and government grant income of $1.2 million.

The increased operating expenses for both the three and nine month periods ended March 31, 2015, compared to the corresponding periods in 2014, primarily related to increased program development costs associated with the pivotal safety and efficacy study for NV-01, proof-of-concept studies for NV-02 and NV-08, increased consulting, accounting and legal fees associated with our initial public offering, and increased expenses associated with building our team and supporting the growth in our operations.

About Nexvet ( www.nexvet.com )

Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share and per share amounts)
     
  March 31, 2015 June 30, 2014
     
Assets    
Current assets    
Cash $ 55,467 $ 30,041
Other income receivable 2,494 2,404
Prepaid expenses and other 957 643
Total current assets 58,918 33,088
Property, plant and equipment, net 555 514
Intangible assets, net 1 2
Total assets $ 59,474 $ 33,604
Liabilities, Convertible Preference Shares and Shareholders' Equity (Deficit)    
Current liabilities    
Accounts payable $ 761 $ 870
Accrued expenses 2,040 2,299
Lease incentive liability 23 28
Total current liabilities 2,824 3,197
Lease incentive liability 66 103
Warrants — 5,435
Total noncurrent liabilities 66 5,538
Total liabilities $ 2,890 $ 8,735
Commitments and contingencies    
Convertible preference shares    
SIRPS, $0.125 nominal value per share, zero and 4,000,000 shares authorized as of March 31, 2015 and June 30, 2014, respectively—zero and 1,737,132 shares issued and outstanding as of March 31, 2015 and June 30, 2014, respectively $ — $ 8,177
Series B, $0.125 nominal value per share, zero and 8,000,000 shares authorized as of March 31, 2015 and June 30, 2014, respectively—zero and 4,200,006 shares issued and outstanding as of March 31, 2015 and June 30, 2014, respectively — 25,649
Total convertible preference shares $ — $ 33,826
Shareholders' equity (deficit)    
Ordinary shares, $0.125 nominal value per share 100,000,000 and 20,000,000 shares authorized as of March 31, 2015 and June 30, 2014, respectively—11,350,845 and 1,268,810 shares issued and outstanding as of March 31, 2015 and June 30, 2014, respectively $ 1,418 $ 126
Euro deferred shares, €100 nominal value per share, 400 and zero shares authorized as of March 31, 2015 and June 30, 2014, respectively—400 and zero shares issued and outstanding as of March 31, 2015 and June 30, 2014, respectively 13 —
Additional paid-in capital 79,079 2,342
Accumulated other comprehensive (loss) income (4,750) 373
Accumulated deficit (19,176) (11,798)
Total shareholders' equity (deficit) 56,584 (8,957)
Total liabilities, convertible preference shares and shareholders' equity (deficit) $ 59,474 $ 33,604
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share amounts)
         
  Three Months Ended March 31, Nine Months Ended March 31,
  2015 2014 2015 2014
Revenue        
Other $ — $ 7 $ 25 $ 7
Total revenue — 7 25 7
Operating Expenses        
Research and development 2,679 1,601 7,444 3,621
General and administrative 2,430 1,099 7,688 2,551
Total operating expenses 5,109 2,700 15,132 6,172
Loss from operations (5,109) (2,693) (15,107) (6,165)
Other Income (Expense)        
Research and development incentive income 1,011 626 2,693 1,443
Government grant income 84 581 403 1,247
Exchange gain (loss) 1,341 (2) 4,595 (41)
Interest income 5 18 38 37
Net loss $ (2,668) $ (1,470) $ (7,378) $ (3,479)
Net loss per share attributable to ordinary shareholders, basic and diluted $ (0.36) $ (1.47) $ (2.30) $ (3.48)
Weighted-average ordinary shares outstanding, basic and diluted 7,474,478 1,000,000 3,204,434 1,000,000
Comprehensive Loss        
Net loss $ (2,668) $ (1,470) $ (7,378) $ (3,479)
Net (loss) gain in foreign currency translation adjustments (1,505) 84 (5,123) 162
Total comprehensive loss $ (4,173) $ (1,386) $ (12,501) $ (3,317)

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements consist of all statements other than statements of historical fact, including, statements regarding our future results of operations and financial position, ability to reach a statistically significant endpoint at the primary assessment of the NV-01 pivotal safety and efficacy study, results of the current, new or any future NV-01 study, future expenditures relating to NV-01, the time for completion of any of our studies, business strategy, prospective products, ability to obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "objective," "plan," "potential," "predict," "project," "position," "seek," "should," "target," "will," "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management's beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors.

Factors that could cause actual results to differ materially from our expectations expressed in this press release include those summarized under Risk Factors in our reports on Forms 10-Q and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Unless otherwise stated or the context otherwise indicates, references to "we," "us," "our," "Nexvet," "Nexvet Biopharma plc" or the "Company" refer to Nexvet Biopharma public limited company and its consolidated subsidiaries.

Further information Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 105 Media Lynn Granito Berry & Co. Public Relations +1 212-253-8881 Company Damian Lismore CFO, Nexvet Biopharma plc +1 415-606-5744

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGi's Four Paths to Global Green Development

Updated Category News Views 41

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 167

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 152

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 249

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

Trade Developments Impacting Global Stocks and Currencies

Updated Category News Views 225

Trade Developments Impacting Global Stocks During the latest trading session in Asia, futures for the S&P 500 and Nasdaq 100 showed positive momentum, increasing by 0.5% and 0.6% respectively. This positive trend comes after Friday's historic closing levels. The surge in optimism can be largely attributed to developments surrounding a trade agreement between the US and...

Continue Reading
Subaru Launches Gear for Good Initiative for Youth Soccer Growth

Updated Category News Views 152

Subaru Champions Youth Soccer with Gear for Good Initiative Subaru of America is proud to announce its engaging initiative, Gear for Good, aimed at nurturing the budding talent in youth soccer. This project represents Subaru's unwavering commitment to community involvement, ensuring that every child has access to the necessary tools to pursue their passion for soccer....

Continue Reading
Discover Nykredit's Upcoming Mortgage Bond Auction Insights

Updated Category News Views 306

Nykredit's Mortgage Bond Auction Overview Nykredit Realkredit A/S, a prominent financial institution, is organizing an exciting auction designed for interested investors. This event aims to enhance participation in the mortgage bond market, making it a notable opportunity for those seeking investment options. What to Expect at the Auction Scheduled for a future date, the...

Continue Reading
Paperclip Partners with Apis Productions for Robust Data Security

Updated Category News Views 106

Paperclip Collaborates with Apis Productions for Enhanced Security In an exciting new development, Paperclip, Inc. (OTCMKTS: PCPJ) has announced its partnership with Apis Productions to launch cutting-edge data security solutions. This collaboration focuses on integrating Paperclip’s innovative SAFE encryption technology within Apis Productions’ insurance technology...

Continue Reading
Medical Imaging Equipment Services Market Set for Growth Surge

Updated Category News Views 91

Overview of the Medical Imaging Equipment Services Market The Medical Imaging Equipment Services Market is set for a period of substantial growth, with projections indicating an increase from USD 60 billion in 2024 to USD 85 billion by 2031. This growth trajectory correlates with a compound annual growth rate (CAGR) of 5.0%. Several factors are contributing to this steady...

Continue Reading